Health Industry Watch
SEE OTHER BRANDS

Your healthcare and wellness news reporter

Health Industry Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.

Press releases published on April 29, 2025

Skye Bioscience to Participate in May Investment and Medical Conferences

Skye Bioscience to Participate in May Investment and Medical Conferences

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will …

EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy

EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy

Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical trial for patients with relapse or refractory multiple …

Ostarine Mk-2866 SARMs: Ostarine Cycle, Osta 2866 Benefits, Ostarine PCT, Ostarine Mk-2866 Dosage, Osta 2866 Side Effects, What Is Ostarine, Buy, Before and After By CrazyBulk

Ostarine Mk-2866 SARMs: Ostarine Cycle, Osta 2866 Benefits, Ostarine PCT, Ostarine Mk-2866 Dosage, Osta 2866 Side Effects, What Is Ostarine, Buy, Before and After By CrazyBulk

New York , April 29, 2025 (GLOBE NEWSWIRE) -- NEW YORK, April 28, 2025: Crazy Bulk OSTA 2866: A Safe Alternative to Ostarine MK 2866  Crazy Bulk OSTA 2866 is a safe and legal substitute for Ostarine MK 2866. We now have a new type of bodybuilding …

Regeneron Reports First Quarter 2025 Financial and Operating Results

Regeneron Reports First Quarter 2025 Financial and Operating Results

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22 First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 billion versus first quarter 2024 First quarter 2025 EYLEA …

Semen & Cum Pills - Best Volume Pills of 2025 (Supplements for Bigger Loads) - By Semanax

Semen & Cum Pills - Best Volume Pills of 2025 (Supplements for Bigger Loads) - By Semanax

Limassol, Cyprus, April 29, 2025 (GLOBE NEWSWIRE) -- Particularly in the male enhancement pills industry, Semenax Volume Pills are arguably the best rated and most trusted cum pills for men wanting to increase the volume of their semen, heighten their …

Prime Biome Safety Report 2025: Exposing Review Scams, Customer Complaints & Safe Buying Options

Prime Biome Safety Report 2025: Exposing Review Scams, Customer Complaints & Safe Buying Options

St. Petersburg, Florida, April 29, 2025 (GLOBE NEWSWIRE) -- PrimeBiome is kind of blowing up right now (Rating: 4.97/5), and for good reason. People are raving about smoother digestion, way less bloating, and that glow-up skin vibe. It's a smart, science- …

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries  BROOMFIELD, Colo., …

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a. …

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on …

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

- ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure - - Approval based on the pivotal Phase 3 VIITAL™ study, showing ZEVASKYN resulted in significant wound healing and pain reduction after a …

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief …

ProDentim Reviews (ALERT): I TRIED IT, Tracked It, and Exposed the Good, Bad & Unexpected

ProDentim Reviews (ALERT): I TRIED IT, Tracked It, and Exposed the Good, Bad & Unexpected

Tallmadge, Ohio, April 29, 2025 (GLOBE NEWSWIRE) -- ProDentim is rated 5 stars by over 95,000 satisfied customers. It combines 3.5 billion CFUs of powerful probiotics, including Lactobacillus Paracasei, B.lactis BL-04®, and Lactobacillus Reuteri, along …

Britisches Unternehmen Stablepharma Ltd. beginnt mit klinischen Studien der Phase I für den weltweit ersten ohne Kühlung auskommenden Tetanus- und Diphtherie-Impfstoff

Britisches Unternehmen Stablepharma Ltd. beginnt mit klinischen Studien der Phase I für den weltweit ersten ohne Kühlung auskommenden Tetanus- und Diphtherie-Impfstoff

LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Nach der MHRA-Zulassung hat Stablepharma Ltd eine klinische Studie der Phase I mit seinem Hauptkandidaten, dem kühlschrankfreien Tetanus- und Diphtherieimpfstoff SPVX02, begonnen. Die klinische Phase-I-Studie am …

L’entreprise de biotechnologie britannique Stablepharma Ltd. lance en première mondiale un essai de Phase I ciblé sur un vaccin thermostable contre le tétanos et la diphtérie

L’entreprise de biotechnologie britannique Stablepharma Ltd. lance en première mondiale un essai de Phase I ciblé sur un vaccin thermostable contre le tétanos et la diphtérie

LONDRES, 29 avr. 2025 (GLOBE NEWSWIRE) -- Après avoir obtenu l’autorisation de la MHRA, l’autorité britannique de réglementation du marché des dispositifs médicaux, Stablepharma Ltd. entre en essai clinique de Phase I pour son principal candidat, SPVX02, …

Microbiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma

Microbiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma

CAMBRIDGE, United Kingdom, April 29, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism …

DEBRA Research Announces Impact Investment into Nova Anchora to Advance Protein Therapy for Epidermolysis Bullosa

DEBRA Research Announces Impact Investment into Nova Anchora to Advance Protein Therapy for Epidermolysis Bullosa

Additional investors include global investment firm Viking Global Investors, charity foundation CureEB, the Epidermolysis Bullosa Medical Research Foundation (EBMRF), and Stanford University. The financing will enable Nova Anchora to advance its lead …

deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection

deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection

deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection Round co-led by Columbus Venture Partners, Panakès Partners and Mérieux Equity Partners Barcelona, Spain – 29 …

MTA Strengthens Global Event Operations to Better Support Customers with Strategic Regional Hubs

MTA Strengthens Global Event Operations to Better Support Customers with Strategic Regional Hubs

BARCELONA, Spain, April 29, 2025 (GLOBE NEWSWIRE) -- Miller Tanner Associates (MTA), a leader in global event operations for 28 years, today announced from the Outsourcing in Clinical Trials Europe 2025 conference in Barcelona, Spain, that it has …

Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung

Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung

Pratteln, Schweiz, 29. April 2025 - Santhera Pharmaceuticals (SIX: SANN) hat heute die Einladung zur ordentlichen Generalversammlung (GV) veröffentlicht, die am 20. Mai 2025 um 10:00 Uhr MESZ im Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Schweiz, …

Santhera Publishes Agenda for its Annual General Meeting

Santhera Publishes Agenda for its Annual General Meeting

Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 20, 2025, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service